blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2033660

EP2033660 - Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  12.02.2010
Database last updated on 12.11.2024
Most recent event   Tooltip12.02.2010Application deemed to be withdrawnpublished on 17.03.2010  [2010/11]
Applicant(s)For all designated states
Freie Universität Berlin
Kaiserswerther Strasse 16-18
14195 Berlin / DE
For all designated states
Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin / DE
[N/P]
Former [2009/11]For all designated states
Freie Universität Berlin
Kaiserswerther Strasse 16-18
14195 Berlin / DE
For all designated states
Charité-Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin / DE
Inventor(s)01 / Reissig, Hans-Urlich
Wulfstrasse 15
12165 Berlin / DE
02 / Dernedde, Jens
Niebuhrstrasse 72
10629 Berlin / DE
03 / Schlecht, Sabine
Wilhelmstrasse 5
10963 Berlin / DE
04 / Roskamp, Meike
Bundesallee 198
10717 Berlin / DE
 [2009/11]
Representative(s)Engelhard, Markus
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München / DE
[N/P]
Former [2009/11]Engelhard, Markus
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date07017412.305.09.2007
[2009/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2033660
Date:11.03.2009
Language:EN
[2009/11]
Search report(s)(Supplementary) European search report - dispatched on:EP31.03.2008
ClassificationIPC:A61K47/48, A61P29/00, A61P17/06, A61P11/06, A61P19/02, A61P37/06, A61P37/00
[2009/11]
CPC:
A61K47/6923 (EP); A61P11/06 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P29/00 (EP); A61P37/00 (EP);
A61P37/06 (EP) (-)
Designated contracting states[2009/47]
Former [2009/11]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Funktionalisierte Nanopartikel zur Hemmung Selectin-vermittelter Zelladhäsion[2009/11]
English:Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion[2009/11]
French:Nanoparticules fonctionnalisées pour l'inhibition d'adhésion de cellule au moyen d'une sélection[2009/11]
Examination procedure12.09.2009Application deemed to be withdrawn, date of legal effect  [2010/11]
20.10.2009Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2010/11]
Fees paidPenalty fee
Additional fee for renewal fee
30.09.200903   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO0232404  (CONSEJO SUPERIOR INVESTIGACION [ES], et al) [X] 1-12,15-19,21,22 * claims 1,15,24 * * page 3, lines 22-28 * * page 5, lines 6-12 * * page 11, line 11 - page 12, line 12 * * page 13, lines 4-14 * * page 25 - page 27 * * page 25, lines 11-13 * * page 26, lines 24-32 * * page 28, lines 15-19 * * figure 1 *;
 [X]WO2006037081  (UNIV CALIFORNIA [US], et al) [X] 1-9,15-17 * page 6, paragraph 2 * * claims 11,16 * * page 24, paragraph LAST - page 25, paragraph 1; example 1 * * page 25, paragraph LAST * * page 5, paragraph 2 * * page 18, paragraph 1 * * page 20, paragraphs 1,2 *;
 [X]WO0241826  (NANOSOLUTIONS GMBH [DE], et al) [X] 1-9,15,16 * page 7, line 4 - page 8, line 18 * * page 9, lines 21-26 * * page 10, lines 4-15 * * figure 3 * * page 23, lines 20-35 * * claims 6,13 *;
 [A]US2005003459  (KRUTZIK SIEGFRIED RICHARD [US]) [A] 1-9,15,16 * claim 130 * * claims 142-147 *
 [X]  - WAYNE SPEVAK ET AL, "Carbohydrates in an acidic multivalent assembly: Nanomolar P-selectin inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1996), vol. 39, no. 5, ISSN 0022-2623, pages 1018 - 1020, XP002393863 [X] 1,4,5,8-13,15,17-22 * page 1018, column 1, paragraph 1 * * page 1018, column 2, paragraph 1 - page 1019, column 2, paragraph 1 * * figures 1,2 *

DOI:   http://dx.doi.org/10.1021/jm950914+
 [A]  - YAREMA K J ET AL, "CHEMICAL APPROACHES TO GLYCOBIOLOGY AND EMERGING CARBOHYDRATE-BASED THERAPEUTIC AGENTS", CURRENT OPINION IN CHEMICAL BIOLOGY, CURRENT BIOLOGY LTD, LONDON, GB, (1998), vol. 2, no. 1, ISSN 1367-5931, pages 49 - 61, XP000979483 [A] 1-22 * page 50, column 1, paragraph LAST - page 51, column 2, paragraph 4 *

DOI:   http://dx.doi.org/10.1016/S1367-5931(98)80035-5
 [A]  - YEKTA S ET AL, "Simple modifications of enantiopure 1,2-oxazines leading to building blocks for carbohydrate and peptide mimetics", SYNLETT 20070813 DE, (20070813), no. 13, ISSN 0936-5214, pages 2069 - 2072, XP008089227 [A] 1-22 * compound 7 * * page 2069, column 1, paragraph 1 - column 2, paragraph 1 * * page 2071, column 1, paragraph 2 * * page 2072, paragraph 19 *
 [A]  - KAILA N ET AL, "Selectin inhibitors", EXPERT OPINION ON THERAPEUTIC PATENTS 01 MAR 2003 UNITED KINGDOM, (20030301), vol. 13, no. 3, ISSN 1354-3776, pages 305 - 317, XP002470966 [A] 1-22 * page 307, column 1, paragraph 2 - column 2, paragraph 1 * * page 311, column 2, paragraph 3 *

DOI:   http://dx.doi.org/10.1517/13543776.13.3.305
 [A]  - WILKINS P ET AL, "Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (19950929), vol. 270, no. 39, ISSN 0021-9258, pages 22677 - 22680, XP002111841 [A] 1-22 * page 22677, column 2, paragraph 3 *

DOI:   http://dx.doi.org/10.1074/jbc.270.39.22677
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.